AstraZeneca Snags Stake In Acerta … | Chemical & Engineering News
Volume 93 Issue 49 | p. 13 | Concentrates
Issue Date: December 21, 2015

AstraZeneca Snags Stake In Acerta …

Department: Business
Keywords: pharmaceuticals, biotech, M&A, BTK inhibitors, cancer

AstraZeneca has agreed to pay $4 billion for a 55% stake in privately held Acerta Pharma. The centerpiece of the deal is acalabrutinib, a second-generation BTK inhibitor in Phase III studies to treat certain blood cancers. If successful, the molecule would compete with Imbruvica, an approved BTK inhibitor developed by Pharmacyclics, which AbbVie acquired earlier this year for $21 billion. AstraZeneca has also secured an option to acquire the remaining shares in Acerta for roughly $3 billion.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment